Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S52-S56

  Powers, John H ^a   Howard, Kellee ^b   Saretsky, Todd ^b   Clifford, Sarah ^b   Hoffmann, Steve ^c   Llorens, Lily ^d   Talbot, George ^e  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b ICON PLC   (United Kingdom)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Llorens Consulting   (United States)

^e Talbot Advisors LLC   (United States)

Author keywords

clinical practice; clinical trials; endpoints; Infectious diseases; Patient Reported outcomes

Indexed keywords

ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; OUTCOME ASSESSMENT; PATIENT-REPORTED OUTCOME; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; COMMUNICABLE DISEASE; PRACTICE GUIDELINE;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; HUMANS; PATIENT OUTCOME ASSESSMENT; PRACTICE GUIDELINES AS TOPIC;

EID: 85010905736     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw317     Document Type: Article

References (45)

1. Durham LK, Ge M, Guccia AJ, Quinn JP. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis 2010; 29:353-6.
2. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013:114.
4. Boucher HW, Talbot GH, Benjamin DK, et al. 10×'20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-94.
5. Dutton G. Biopharmas drive antibiotic development, 2013. Available at: http://www.genengnews.com/insight-and-intelligenceand153/biopharmas-driveantibiotic-development/77899874/. Accessed 8 December 2015.
6. Kermani F. Boosting new antibiotic drug development in Europe. Pharm Technol 2014; 38.
7. World Alliance Against Antibiotic Resistance. Safeguarding antibiotics. Available at: http://www.infectiologie.com/site/waaar.php. Accessed 9 January 2015.
8. Innovative Medicines Initiative. New drugs for bad bugs, 2010. Available at: http://www.imi.europa.eu/content/nd4bb. Accessed 23 May 2016.
9. Infectious Diseases Society of America. Antibiotic development: the 10×'20 Initiative. Available at: http://www.idsociety.org/10×20/. Accessed 23 May 2016.
10. National Institute for Health Research. Antimicrobial resistance themed call. Available at: http://www.themedcalls.nihr.ac.uk/amr. Accessed 9 January 2015.
11. Partnership to Advance Clinical electronic Research (PACeR). Available at: http://pacerhealth.org/about/. Accessed 23 May 2016.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: statistical principles for clinical trials E9. Geneva, Switzerland: ICH, 1998.
13. US Food and Drug Administration. Guidance for industry and investigators, safety reporting requirements for INDs and BA/BE studies. Rockville, MD: FDA, 2012:32.
14. European Medicines Agency and Committee for Human Medicinal Products (CHMP). Guideline on key aspects for the use of pharmacogenomics in the pharmacovigilance of medicinal products. London, UK: EMA, 2015:19.
15. US Food and Drug Administration. Safety assessment for IND safety reporting: guidance for industry. Silver Spring, MD: FDA, 2015.
16. Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitlin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. Am J Ther 2015; 22:117-24.
17. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13:269-75.
18. Bettiol E, Wetherington JD, Schmitt N, Harbarth S; COMBACTE Consortium. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals. Antimicrob Agents Chemother 2015; 59:3695-9.
19. Alemayehu D, Quinn J, Cook J, Kunkel M, Knirsch C. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. Clin Infect Dis 2012; 55:562-7.
20. Eisenstein EL, Lemons PW 2nd, Tardiff BE, Schulman KA, Jolly MK, Califf RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J 2005; 149:482-8.
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
22. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, reasons for stopping study treatment. Eur Heart J 2013; 34:1279-91.
23. HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203-12.
24. Kaiser LD, Melemed AS, Preston AJ, et al. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 2010; 28:5046-53.
25. Clinical Trials Transformation Initiative. QbD: project summary. Available at: http://www.ctti-clinicaltrials.org/what-we-do/investigational-plan/qbd-qrm. Accessed 1 December 2015.
26. Clinical Trials Transformation Initiative. CTTI recommendations: quality by design. Available at: http://www.ctti-clinicaltrials.org/files/QbD-toolkit/CTTI% 20Quality%20by%20Design%20Recommendations-FINAL-1JUN15.pdf. Accessed 1 December 2015.
27. US Food and Drug Administration. Guidance for industry hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment (draft guidance, revision 2). Rockville, MD, 2014:19.
28. European Medicines Agency and Committee for Human Medicinal Products. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. London, UK: EMA, 2011:25.
29. European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. London, UK: EMA, 2013:20.
30. Official Journal of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the council of 16 April 2014 on clinical trials on medicinal products for human use, repealing directive 2001/20/EC.
31. Clinical Trials Transformation Initiative. Streamlining HABP/VABP trials: project summary. Available at: http://www.ctti-clinicaltrials.org/what-we-do/ctti-projects/habpvabp-trials. Accessed 1 December 2015.
32. US Food and Drug Administration. Guidance for industry determining the extent of safety data collection needed in late stage premarket and postapproval clinical investigations. Rockville, MD: FDA, 2012:12.
33. US Food and Drug Administration. Draft guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: FDA, 2006:36.
34. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189:250-5.
35. Turner D, Schunemann HJ, Griffith LE, et al. Theminimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010; 63:28-36.
36. US Food and Drug Administration. Guidance for industry, antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Rockville, MD: FDA, 2013:15.
37. Getz K. Improving protocol design feasibility to drive drug development economics and performance. Int J Environ Res Public Health 2014; 11:5069-80.
38. Weisfeld N, English R, Claiborne A. Envisioning a transformed clinical trials enterprise in the United States: establishing an agenda for 2020. Washington, DC: The National Academies Press, 2012:232.
39. Mobi Health News. Epic Systems launches iPhone HER app, Haiku, 2013. Available at: http://mobihealthnews.com/6030/epic-systems-launches-iphone-ehr-apphaiku/. Accessed 9 January 2015.
40. TransCelerate BioPharma Inc. Our initiatives. Available at: http://www.transceleratebiopharmainc.com/initiatives/. Accessed 17 December 2015.
41. US Food and Drug Administration. Guidance for industry: oversight of clinical investigations-a risk-based approach to monitoring. Silver Spring, MD: FDA, 2013:22.
42. US Food and Drug Administration. Guidance for industry: electronic source data in clinical investigations. Silver Spring, MD: FDA, 2013:15.
43. European Medicines Agency. Reflection paper on expectations for electronic source data and data transcribed to electronic data collection tools in clinical trials. London, UK: EMA, 2010:13.
44. European Medicines Agency. Reflection paper on risk based quality management in clinical trials. London, UK: EMA, 2011.
45. US Food and Drug Administration. Providing regulatory submissions in electronic format-standardized study data (guidance for industry). Silver Spring, MD: FDA, 2014:15.